Skip to main content
. Author manuscript; available in PMC: 2019 Oct 2.
Published in final edited form as: Circulation. 2018 Oct 2;138(14):1431–1445. doi: 10.1161/CIRCULATIONAHA.117.031231

Figure 8. AAV5-Gal-1 by single injection significantly decreases blood pressure of SHR.

Figure 8

(A) Schematic diagrams of AAV5-Gal-1 and control AAV5-GFP. (B) Tissue-selective expression of exogenous Flag-Gal-1 delivered by AAV5 in SHR. MA: mesenteric artery. (C, D) Western blots and quantification of Exogenous Flag-Gal-1, Gal-1 or CaV1.2 in thoracic aorta in AAV5-Gal-1 or AAV5-GFP-treated SHR (n=3). (E–J) Compared to control AAV5-GFP (1×1013 vg/kg, n=4), from day 7 onwards, SHR subject to single injection of AAV5-Gal-1 (1×1013 vg/kg, n=3) reached a maximal reduction of the systolic BP (SBP) at about 27 mmHg (E, F), the diastolic BP (DBP) at about 20 mmHg (G, H) and the mean arterial pressure (MAP) at about 23 mmHg (I, J), respectively, and remain reduced until day 30. Mean SBP (F), DBP (H) and MAP (J) stands for the average blood pressure from day 7 to day 30. Data were shown as mean ± SEM. *p<0.05, ***p<0.001 versus AAV5-GFP group.